Goldman Sachs analyst Salveen Richter raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $32 from $28 and keeps a Neutral rating on the shares. Shares rose after announcing plans to seek accelerated FDA approval for mitapivat in sickle cell disease, following a pre-sNDA meeting, with the confirmatory trial protocol submitted and no expected impact on FY26 OpEx, the analyst tells investors in a research note. The update supports a positive regulatory outlook and a potential third commercial launch for mitapivat, the firm says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
- Agios Pharmaceuticals: Mitapivat’s Accelerated Approval Path and De-Risked Sickle Cell Opportunity Support Buy Rating
- Agios up 13% at $33.50 after announcing pursuit of approval for mitapivat
- Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat
- Citi ups Agios target, opens ‘upside 90-day catalyst watch’